Impact of obesity on outcomes after definitive dose-escalated intensity-modulated radiotherapy for localized prostate cancer

Lora S. Wang, Colin T. Murphy, Karen Ruth, Nicholas G. Zaorsky, Marc C. Smaldone, Mark L. Sobczak, Alexander Kutikov, Rosalia Viterbo, Eric M. Horwitz

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

BACKGROUND Previous publications have demonstrated conflicting results regarding body mass index (BMI) and prostate cancer (CaP) outcomes after definitive radiotherapy (RT) before the dose escalation era. The goal of the current study was to determine whether increasing BMI was associated with outcomes in men with localized CaP who were treated with dose-escalated RT. METHODS The authors identified patients with localized (T1b-T4N0M0) CaP who were treated with definitive intensity-modulated RT and image-guided RT from 2001 through 2010. BMI was analyzed as a continuous variable. Adjusting for confounders, multivariable competing risk and Cox proportional hazards regression models were used to assess the association between BMI and the risk of biochemical failure (BF), distant metastases (DM), cause-specific mortality (CSM), and overall mortality. RESULTS Of the 1442 patients identified, approximately 20% had a BMI <25 kg/m2, 48% had a BMI of 25 to 29.9 kg/m2, 23% had a BMI of 30 to 34.9 kg/m2, 6% had a BMI of 35 to 39.9 kg/m2, and 4% had a BMI of ≥40 kg/m2. The median follow-up was 47.6 months (range, 1-145 months), with a median age of 68 years (range, 36-89 years). The median dose was 78 grays (range, 76-80 grays) and 30% of patients received androgen deprivation therapy. Increasing BMI was found to be inversely associated with age (P<.001) and pretreatment prostate-specific antigen level (P = .018). On multivariable analysis, increasing BMI was associated with an increased risk of BF (hazard ratio [HR], 1.03; 95% confidence interval [95% CI], 1.00-1.07 [P = .042]), DM (HR, 1.07; 95% CI, 1.02-1.11 [P = .004]), CSM (HR, 1.15; 95% CI, 1.07-1.23 [P<.001]), and overall mortality (HR, 1.05; 95% CI, 1.02-1.08 [P = .004]). CONCLUSIONS For patients with CaP receiving dose-escalated intensity-modulated RT with daily image-guidance, increasing BMI appears to be associated with an increased risk of BF, DM, CSM, and overall mortality. Cancer 2015;121:3010-3017.

Original languageEnglish (US)
Pages (from-to)3010-3017
Number of pages8
JournalCancer
Volume121
Issue number17
DOIs
StatePublished - Sep 1 2015

Fingerprint

Intensity-Modulated Radiotherapy
Prostatic Neoplasms
Body Mass Index
Obesity
Mortality
Confidence Intervals
Neoplasm Metastasis
Radiotherapy
Image-Guided Radiotherapy
Prostate-Specific Antigen
Proportional Hazards Models
Androgens

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Wang, L. S., Murphy, C. T., Ruth, K., Zaorsky, N. G., Smaldone, M. C., Sobczak, M. L., ... Horwitz, E. M. (2015). Impact of obesity on outcomes after definitive dose-escalated intensity-modulated radiotherapy for localized prostate cancer. Cancer, 121(17), 3010-3017. https://doi.org/10.1002/cncr.29472
Wang, Lora S. ; Murphy, Colin T. ; Ruth, Karen ; Zaorsky, Nicholas G. ; Smaldone, Marc C. ; Sobczak, Mark L. ; Kutikov, Alexander ; Viterbo, Rosalia ; Horwitz, Eric M. / Impact of obesity on outcomes after definitive dose-escalated intensity-modulated radiotherapy for localized prostate cancer. In: Cancer. 2015 ; Vol. 121, No. 17. pp. 3010-3017.
@article{b1da0e6a9fde4b97bb44cafd816421b0,
title = "Impact of obesity on outcomes after definitive dose-escalated intensity-modulated radiotherapy for localized prostate cancer",
abstract = "BACKGROUND Previous publications have demonstrated conflicting results regarding body mass index (BMI) and prostate cancer (CaP) outcomes after definitive radiotherapy (RT) before the dose escalation era. The goal of the current study was to determine whether increasing BMI was associated with outcomes in men with localized CaP who were treated with dose-escalated RT. METHODS The authors identified patients with localized (T1b-T4N0M0) CaP who were treated with definitive intensity-modulated RT and image-guided RT from 2001 through 2010. BMI was analyzed as a continuous variable. Adjusting for confounders, multivariable competing risk and Cox proportional hazards regression models were used to assess the association between BMI and the risk of biochemical failure (BF), distant metastases (DM), cause-specific mortality (CSM), and overall mortality. RESULTS Of the 1442 patients identified, approximately 20{\%} had a BMI <25 kg/m2, 48{\%} had a BMI of 25 to 29.9 kg/m2, 23{\%} had a BMI of 30 to 34.9 kg/m2, 6{\%} had a BMI of 35 to 39.9 kg/m2, and 4{\%} had a BMI of ≥40 kg/m2. The median follow-up was 47.6 months (range, 1-145 months), with a median age of 68 years (range, 36-89 years). The median dose was 78 grays (range, 76-80 grays) and 30{\%} of patients received androgen deprivation therapy. Increasing BMI was found to be inversely associated with age (P<.001) and pretreatment prostate-specific antigen level (P = .018). On multivariable analysis, increasing BMI was associated with an increased risk of BF (hazard ratio [HR], 1.03; 95{\%} confidence interval [95{\%} CI], 1.00-1.07 [P = .042]), DM (HR, 1.07; 95{\%} CI, 1.02-1.11 [P = .004]), CSM (HR, 1.15; 95{\%} CI, 1.07-1.23 [P<.001]), and overall mortality (HR, 1.05; 95{\%} CI, 1.02-1.08 [P = .004]). CONCLUSIONS For patients with CaP receiving dose-escalated intensity-modulated RT with daily image-guidance, increasing BMI appears to be associated with an increased risk of BF, DM, CSM, and overall mortality. Cancer 2015;121:3010-3017.",
author = "Wang, {Lora S.} and Murphy, {Colin T.} and Karen Ruth and Zaorsky, {Nicholas G.} and Smaldone, {Marc C.} and Sobczak, {Mark L.} and Alexander Kutikov and Rosalia Viterbo and Horwitz, {Eric M.}",
year = "2015",
month = "9",
day = "1",
doi = "10.1002/cncr.29472",
language = "English (US)",
volume = "121",
pages = "3010--3017",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "17",

}

Wang, LS, Murphy, CT, Ruth, K, Zaorsky, NG, Smaldone, MC, Sobczak, ML, Kutikov, A, Viterbo, R & Horwitz, EM 2015, 'Impact of obesity on outcomes after definitive dose-escalated intensity-modulated radiotherapy for localized prostate cancer', Cancer, vol. 121, no. 17, pp. 3010-3017. https://doi.org/10.1002/cncr.29472

Impact of obesity on outcomes after definitive dose-escalated intensity-modulated radiotherapy for localized prostate cancer. / Wang, Lora S.; Murphy, Colin T.; Ruth, Karen; Zaorsky, Nicholas G.; Smaldone, Marc C.; Sobczak, Mark L.; Kutikov, Alexander; Viterbo, Rosalia; Horwitz, Eric M.

In: Cancer, Vol. 121, No. 17, 01.09.2015, p. 3010-3017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Impact of obesity on outcomes after definitive dose-escalated intensity-modulated radiotherapy for localized prostate cancer

AU - Wang, Lora S.

AU - Murphy, Colin T.

AU - Ruth, Karen

AU - Zaorsky, Nicholas G.

AU - Smaldone, Marc C.

AU - Sobczak, Mark L.

AU - Kutikov, Alexander

AU - Viterbo, Rosalia

AU - Horwitz, Eric M.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - BACKGROUND Previous publications have demonstrated conflicting results regarding body mass index (BMI) and prostate cancer (CaP) outcomes after definitive radiotherapy (RT) before the dose escalation era. The goal of the current study was to determine whether increasing BMI was associated with outcomes in men with localized CaP who were treated with dose-escalated RT. METHODS The authors identified patients with localized (T1b-T4N0M0) CaP who were treated with definitive intensity-modulated RT and image-guided RT from 2001 through 2010. BMI was analyzed as a continuous variable. Adjusting for confounders, multivariable competing risk and Cox proportional hazards regression models were used to assess the association between BMI and the risk of biochemical failure (BF), distant metastases (DM), cause-specific mortality (CSM), and overall mortality. RESULTS Of the 1442 patients identified, approximately 20% had a BMI <25 kg/m2, 48% had a BMI of 25 to 29.9 kg/m2, 23% had a BMI of 30 to 34.9 kg/m2, 6% had a BMI of 35 to 39.9 kg/m2, and 4% had a BMI of ≥40 kg/m2. The median follow-up was 47.6 months (range, 1-145 months), with a median age of 68 years (range, 36-89 years). The median dose was 78 grays (range, 76-80 grays) and 30% of patients received androgen deprivation therapy. Increasing BMI was found to be inversely associated with age (P<.001) and pretreatment prostate-specific antigen level (P = .018). On multivariable analysis, increasing BMI was associated with an increased risk of BF (hazard ratio [HR], 1.03; 95% confidence interval [95% CI], 1.00-1.07 [P = .042]), DM (HR, 1.07; 95% CI, 1.02-1.11 [P = .004]), CSM (HR, 1.15; 95% CI, 1.07-1.23 [P<.001]), and overall mortality (HR, 1.05; 95% CI, 1.02-1.08 [P = .004]). CONCLUSIONS For patients with CaP receiving dose-escalated intensity-modulated RT with daily image-guidance, increasing BMI appears to be associated with an increased risk of BF, DM, CSM, and overall mortality. Cancer 2015;121:3010-3017.

AB - BACKGROUND Previous publications have demonstrated conflicting results regarding body mass index (BMI) and prostate cancer (CaP) outcomes after definitive radiotherapy (RT) before the dose escalation era. The goal of the current study was to determine whether increasing BMI was associated with outcomes in men with localized CaP who were treated with dose-escalated RT. METHODS The authors identified patients with localized (T1b-T4N0M0) CaP who were treated with definitive intensity-modulated RT and image-guided RT from 2001 through 2010. BMI was analyzed as a continuous variable. Adjusting for confounders, multivariable competing risk and Cox proportional hazards regression models were used to assess the association between BMI and the risk of biochemical failure (BF), distant metastases (DM), cause-specific mortality (CSM), and overall mortality. RESULTS Of the 1442 patients identified, approximately 20% had a BMI <25 kg/m2, 48% had a BMI of 25 to 29.9 kg/m2, 23% had a BMI of 30 to 34.9 kg/m2, 6% had a BMI of 35 to 39.9 kg/m2, and 4% had a BMI of ≥40 kg/m2. The median follow-up was 47.6 months (range, 1-145 months), with a median age of 68 years (range, 36-89 years). The median dose was 78 grays (range, 76-80 grays) and 30% of patients received androgen deprivation therapy. Increasing BMI was found to be inversely associated with age (P<.001) and pretreatment prostate-specific antigen level (P = .018). On multivariable analysis, increasing BMI was associated with an increased risk of BF (hazard ratio [HR], 1.03; 95% confidence interval [95% CI], 1.00-1.07 [P = .042]), DM (HR, 1.07; 95% CI, 1.02-1.11 [P = .004]), CSM (HR, 1.15; 95% CI, 1.07-1.23 [P<.001]), and overall mortality (HR, 1.05; 95% CI, 1.02-1.08 [P = .004]). CONCLUSIONS For patients with CaP receiving dose-escalated intensity-modulated RT with daily image-guidance, increasing BMI appears to be associated with an increased risk of BF, DM, CSM, and overall mortality. Cancer 2015;121:3010-3017.

UR - http://www.scopus.com/inward/record.url?scp=84939575028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939575028&partnerID=8YFLogxK

U2 - 10.1002/cncr.29472

DO - 10.1002/cncr.29472

M3 - Article

C2 - 26033633

AN - SCOPUS:84939575028

VL - 121

SP - 3010

EP - 3017

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 17

ER -